Kite has exercised its licence option for ACLX-001 of Arcellx in multiple myeloma. Credit: Nemes Laszlo / Shutterstock.com.

Gilead company Kite has expanded its existing partnership with Arcellx for the latter’s CART-ddBCMA candidate to include lymphomas.

The parties entered an international strategic deal in December 2022 to jointly develop and market a CART-ddBCMA candidate for relapsed or refractory multiple myeloma.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Kite has now exercised its licence option for ACLX-001, an ARC-SparX programme of Arcellx in multiple myeloma.

Arcellx is entitled to receive an equity investment of $200m in exchange for 3,242,542 shares of its common stock.

The funding will offer 13% ownership of Arcellx to Gilead.

Arcellx is also eligible to receive $85m in upfront non-dilutive cash payment, separately from milestone payments in the future.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The deal will close by the end of 2023.

A BCMA-specific CAR-modified T-cell therapy of Arcellx, CART-ddBCMA is currently in a Phase II clinical trial. 

Kite executive vice-president Cindy Perettie stated: “We are pleased to see the momentum with the CART-ddBCMA multiple myeloma programme, enabling Kite to enter an area of high unmet need and bring a new, potentially best-in-class cell therapy to patients.

“Given this, we are deepening our relationship with Arcellx to further support the advancement of CART-ddBCMA, bolster our pipeline in multiple myeloma [and] access opportunities in lymphoma.

“In expanding our strategic partnership with Arcellx, we are building upon the established synergy between Arcellx’s platform technologies and Kite’s industry-leading position in CAR T manufacturing and commercialisation.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.